MINNEAPOLIS, April 24, 2026, 17:03 (CDT)
OneMedNet Corporation jumped back over the $1 mark Friday, buoyed by insider filings revealing roughly $1.5 million in commitments to the clinical data outfit. The Nasdaq-listed name, aiming to convert its Palantir-supported platform into steady sales, was trading at $1.10. Volume cleared 11.6 million shares, according to market data.
The clock is ticking. On April 14, Nasdaq notified OneMedNet that its common shares had closed below the $1 minimum bid for 30 straight business days. Now the company faces an Oct. 12 deadline to fix the issue: shares must trade at $1 or higher for at least 10 business days in a row to get back in line.
Just two days earlier, OneMedNet announced its iRWD platform—powered by Palantir Foundry—was live, offering searchable access to 80 million patient journeys plus billions of records. Real-world data (RWD) captures health and care delivery details outside the clinical trial setting; OneMedNet zeroes in on imaging RWD, pulling together de-identified clinical images and associated records.
Chief Medical Officer Jeffrey Yu picked up 903,614 shares at 83 cents each in an April 1 subscription deal, putting $750,000 into the stock, according to his Form 4. In addition, Yu was granted 219,429 shares instead of cash previously owed, bumping his direct holdings to 8,449,266 shares.
Thomas Kosasa, who serves as director and owns 10% of the company, disclosed picking up 595,238 shares at $0.84 apiece on Feb. 6, then another 280,898 shares at $0.89 each on April 23. The filing categorized both as subscription agreements—$500,000 for the first, $250,000 for the second. After these moves, Kosasa’s total reached 16,661,327 shares.
OneMedNet CEO Aaron Green, in an April 22 statement, said subscription users now “find the data they need in seconds.” The company also noted its network has grown by roughly 70%, now covering 80 million patients and 251 million studies. Access is available for around 47 million tokenized patients via Datavant; tokenization relies on coded IDs to connect records while keeping patient names confidential. GlobeNewswire
OneMedNet is wading into a packed real-world data scene, where much bigger names already dominate. IQVIA claims access to over 1.2 billion non-identified patient records through its real-world evidence operations. TriNetX puts its LIVE network’s reach at more than 300 million de-identified patients, while Komodo Health reports its Healthcare Map tracks upwards of 330 million patient journeys.
OneMedNet is still operating on a smaller scale. According to its annual report, total revenue for 2025 reached $1.4 million, a 111% jump from 2024—mostly thanks to a $1.0 million boost in iRWD data-delivery revenue. The company noted that its legacy BEAM medical imaging exchange platform was shut down in May 2025.
OneMedNet reported April 6 that RWD revenue jumped to $1.254 million—well ahead of last year’s $292,000. Fourth-quarter revenue topped $890,000. CEO Green described 2025 as a “pivotal turning point,” noting the company has moved away from BEAM to concentrate efforts on real-world data. GlobeNewswire
The platform isn’t just a story—there’s a balance-sheet crunch too. OneMedNet logged net losses of $2.8 million for 2025 and $10.1 million in 2024, with an accumulated deficit now sitting at $104.4 million. Year-end cash? Just $0.6 million. The company’s filing flagged “substantial doubt” about its ability to keep operating as a going concern, and signaled it may have to seek more funding to stay afloat.
Now, it’s not the dataset’s size in question, but whether OneMedNet can convert that into subscriptions. The company says it’s aiming for subscription revenue growth and anticipates winning more customers through the second and third quarters. Still, its own filings admit rivals might outgun it on resources, and that competing real-world data technologies could squeeze sales, pricing, and margins.
